Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
What's wrong with Raleigh tap water? Algae bloom at Falls Lake behind the smell, color
Recommended
Top two magnet schools in the US are in Wake County
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
159.62
-7.67 (-4.58%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
10,721,827
Open
167.09
Bid (Size)
159.65 (1)
Ask (Size)
164.11 (1)
Prev. Close
167.29
Today's Range
157.65 - 167.46
52wk Range
130.96 - 182.89
Shares Outstanding
N/A
Dividend Yield
3.71%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 Dividend Stocks to Buy and Hold for the Next Decade
Today 7:15 EDT
You'll get dividends and more with these great stocks.
Via
The Motley Fool
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
April 26, 2024
Investors are struggling to see past the end of Humira's dominance.
Via
The Motley Fool
Performance
YTD
-0.13%
-0.13%
1 Month
-11.49%
-11.49%
3 Month
-2.91%
-2.91%
6 Month
+14.89%
+14.89%
1 Year
+7.22%
+7.22%
More News
Read More
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
April 26, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
April 26, 2024
Via
Benzinga
Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?
April 26, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
AbbVie's Options Frenzy: What You Need to Know
April 23, 2024
Via
Benzinga
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
April 26, 2024
Via
InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
April 26, 2024
Via
Benzinga
AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title
April 26, 2024
Via
Investor's Business Daily
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
April 26, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
April 17, 2024
Via
Benzinga
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
April 25, 2024
Via
Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
April 25, 2024
Via
InvestorPlace
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
April 23, 2024
Via
InvestorPlace
Buying the Dip in These 3 Undervalued Dividend Stocks
April 22, 2024
Via
The Motley Fool
3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip
April 22, 2024
Via
InvestorPlace
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Via
Benzinga
Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income
April 20, 2024
Via
The Motley Fool
Topics
ETFs
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
April 19, 2024
Via
InvestorPlace
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
April 19, 2024
Via
Investor's Business Daily
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
April 18, 2024
Via
Benzinga
Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions
April 17, 2024
Via
Benzinga
Exposures
Product Safety
Powell And The Great Indecision
April 16, 2024
Via
Talk Markets
Topics
Economy
Exposures
Economy
Interest Rates
Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now
April 16, 2024
Via
InvestorPlace
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
April 16, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.